PEAK6 Investments’s Karyopharm Therapeutics KPTI Stock Holding History

PEAK6 Investments’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,000	Closed	-$20.1K	–	4537
2023 Q3	$20.1K	Hold	1,000	–	–	﹤0.01%	3757
2023 Q2	$26.9K	Buy	+1,000	New	+$43.1K	﹤0.01%	3540
2022 Q3	–	Sell	-1,000	Closed	-$26.9K	–	5565
2022 Q2	$26.9K	Buy	+1,000	New	+$91.7K	﹤0.01%	5679

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PEAK6 Investments's KPTI Position: Q4 2023 in Review

PEAK6 Investments sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 303 shares — an estimated $6.1K sold.

PEAK6 Investments first reported a position in KPTI in Q2 2022 and held it in 4 quarters. The position peaked at $58.4K in Q1 2023. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

PEAK6 Investments reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
PEAK6 Investments sold 303 Karyopharm Therapeutics shares in Q4 2023, an estimated $6.1K.
PEAK6 Investments first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 4 quarters.
PEAK6 Investments's Karyopharm Therapeutics position peaked at $58.4K in Q1 2023.
117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.